TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting @ascocancer.bsky.social @iaslc.bsky.social #ASCO24 #ESMOASIA24 #WCLC24 #lcsm #oncology
www.onclive.com/view/tkis-lo...
www.onclive.com/view/tkis-lo...
TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting
The second-line setting for HER2-mutated NSCLC is shifting with TKIs looking to demonstrate efficacy and T-DXd under examination in the frontline now.
www.onclive.com
January 21, 2025 at 2:17 PM
TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting @ascocancer.bsky.social @iaslc.bsky.social #ASCO24 #ESMOASIA24 #WCLC24 #lcsm #oncology
www.onclive.com/view/tkis-lo...
www.onclive.com/view/tkis-lo...
Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC @myESMO #ESMOASIA24 #blcsm #oncology
www.onclive.com/view/durvalu...
www.onclive.com/view/durvalu...
Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC
Durvalumab plus vaccine therapy demonstrated evidence of preliminary antitumor activity without substantial additive toxicity in BCG-unresponsive NMIBC.
www.onclive.com
January 9, 2025 at 4:04 PM
Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC @myESMO #ESMOASIA24 #blcsm #oncology
www.onclive.com/view/durvalu...
www.onclive.com/view/durvalu...
Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer
#ESMOAsia24 #MedTwitter #cervicalcancer
onclive.com/view/iparoml...
#ESMOAsia24 #MedTwitter #cervicalcancer
onclive.com/view/iparoml...
Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer
First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.
onclive.com
January 6, 2025 at 2:12 PM
Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer
#ESMOAsia24 #MedTwitter #cervicalcancer
onclive.com/view/iparoml...
#ESMOAsia24 #MedTwitter #cervicalcancer
onclive.com/view/iparoml...
We’re so lucky our job takes us to amazing places, collaborating with colleagues from around the world
@ascocancer.bsky.social #ESMOCancerMedComm
#ASCOBT24 #ESMOAsia24
@ascocancer.bsky.social #ESMOCancerMedComm
#ASCOBT24 #ESMOAsia24
December 31, 2024 at 3:14 AM
We’re so lucky our job takes us to amazing places, collaborating with colleagues from around the world
@ascocancer.bsky.social #ESMOCancerMedComm
#ASCOBT24 #ESMOAsia24
@ascocancer.bsky.social #ESMOCancerMedComm
#ASCOBT24 #ESMOAsia24
#ESMOAsia24 #ESMO so wonderful to see old colleagues and meet new colleagues from all over #Asia with ONE FOCUS: #CancerResearch #cancer #patientcare #crcsm @vumc-insights.bsky.social #Singapore
December 10, 2024 at 3:04 AM
#ESMOAsia24 #ESMO so wonderful to see old colleagues and meet new colleagues from all over #Asia with ONE FOCUS: #CancerResearch #cancer #patientcare #crcsm @vumc-insights.bsky.social #Singapore
It was a pleasure for us* to meet @michael-jefford.bsky.social who gave an excellent talk on "Improving the model of care for cancer survivors" at #ESMOAsia24
*With my friend and colleague Jiefang, The Lancet Regional Health Western Pacific
*With my friend and colleague Jiefang, The Lancet Regional Health Western Pacific
December 8, 2024 at 3:41 AM
It was a pleasure for us* to meet @michael-jefford.bsky.social who gave an excellent talk on "Improving the model of care for cancer survivors" at #ESMOAsia24
*With my friend and colleague Jiefang, The Lancet Regional Health Western Pacific
*With my friend and colleague Jiefang, The Lancet Regional Health Western Pacific
Great survivorship session at #ESMOAsia24 - thanks for having us, thanks for all who came along!
December 8, 2024 at 3:17 AM
Great survivorship session at #ESMOAsia24 - thanks for having us, thanks for all who came along!
It was a pleasure to meet Dr Aju Mathew in person at the #ESMOAsia24
Do read his Correspondence published in #TheLancet Regional Health Southeast Asia
Legislation on cancer notification in India: current status
www.thelancet.com/journals/lan...
Do read his Correspondence published in #TheLancet Regional Health Southeast Asia
Legislation on cancer notification in India: current status
www.thelancet.com/journals/lan...
December 7, 2024 at 4:03 AM
It was a pleasure to meet Dr Aju Mathew in person at the #ESMOAsia24
Do read his Correspondence published in #TheLancet Regional Health Southeast Asia
Legislation on cancer notification in India: current status
www.thelancet.com/journals/lan...
Do read his Correspondence published in #TheLancet Regional Health Southeast Asia
Legislation on cancer notification in India: current status
www.thelancet.com/journals/lan...
Intracranial germ cell tumours in adolescent and young adults session #ESMOAsia24 #Singapore
Multidisciplinary session on a rare entity chaired by my friend prof Giuseppe Minniti
#radonc #Neuroscience #surgonc #medonc #OncoAlert @oncoalert.bsky.social
Multidisciplinary session on a rare entity chaired by my friend prof Giuseppe Minniti
#radonc #Neuroscience #surgonc #medonc #OncoAlert @oncoalert.bsky.social
December 7, 2024 at 1:50 AM
Intracranial germ cell tumours in adolescent and young adults session #ESMOAsia24 #Singapore
Multidisciplinary session on a rare entity chaired by my friend prof Giuseppe Minniti
#radonc #Neuroscience #surgonc #medonc #OncoAlert @oncoalert.bsky.social
Multidisciplinary session on a rare entity chaired by my friend prof Giuseppe Minniti
#radonc #Neuroscience #surgonc #medonc #OncoAlert @oncoalert.bsky.social
What an honour hosting John Haanen #nki today #NCCS - talking all #celltherapy #TILtherapy & visiting our national GMP facility 👩🏻🔬
And a fascinating talk on myeloids in lung by @charlesswanton.bsky.social ☺️
#ESMOAsia24
And a fascinating talk on myeloids in lung by @charlesswanton.bsky.social ☺️
#ESMOAsia24
December 6, 2024 at 2:47 PM
What an honour hosting John Haanen #nki today #NCCS - talking all #celltherapy #TILtherapy & visiting our national GMP facility 👩🏻🔬
And a fascinating talk on myeloids in lung by @charlesswanton.bsky.social ☺️
#ESMOAsia24
And a fascinating talk on myeloids in lung by @charlesswanton.bsky.social ☺️
#ESMOAsia24
Great time #ESMOAsia24 talking about oligometastatic status and multimodal treatment options for #BreastCancer at the ESMO discussion Hub
Honoured to be introduced by a great friend @kevinpunie.bsky.social
#OncoAlert @oncoalert.bsky.social
Honoured to be introduced by a great friend @kevinpunie.bsky.social
#OncoAlert @oncoalert.bsky.social
December 6, 2024 at 11:57 AM
Great time #ESMOAsia24 talking about oligometastatic status and multimodal treatment options for #BreastCancer at the ESMO discussion Hub
Honoured to be introduced by a great friend @kevinpunie.bsky.social
#OncoAlert @oncoalert.bsky.social
Honoured to be introduced by a great friend @kevinpunie.bsky.social
#OncoAlert @oncoalert.bsky.social
Can we bring 2L PFS closer to 12 months post 1L CDK4/6i? More work needed to improve biomarkers for selection of optimal 2L therapeutic option. #ESMOASIA24
December 6, 2024 at 9:15 AM
Can we bring 2L PFS closer to 12 months post 1L CDK4/6i? More work needed to improve biomarkers for selection of optimal 2L therapeutic option. #ESMOASIA24
At #ESMOAsia24 in Singapore. Big 3 days ahead!
December 6, 2024 at 1:38 AM
At #ESMOAsia24 in Singapore. Big 3 days ahead!
Welcome to #ESMOASIA24
More the 4000 scientists from 68 countries in Singapore 🇸🇬
@oncoalert.bsky.social
More the 4000 scientists from 68 countries in Singapore 🇸🇬
@oncoalert.bsky.social
December 6, 2024 at 1:25 AM
Welcome to #ESMOASIA24
More the 4000 scientists from 68 countries in Singapore 🇸🇬
@oncoalert.bsky.social
More the 4000 scientists from 68 countries in Singapore 🇸🇬
@oncoalert.bsky.social
The largest oncology conference in Asia with over 4,000 participants is about to start. #ESMOAsia24 Singapore
December 6, 2024 at 1:04 AM
The largest oncology conference in Asia with over 4,000 participants is about to start. #ESMOAsia24 Singapore
Last work trip / conference / invited talk for the year 😮💨
See you at #ESMOAsia24 ?
See you at #ESMOAsia24 ?
December 4, 2024 at 10:40 PM
Last work trip / conference / invited talk for the year 😮💨
See you at #ESMOAsia24 ?
See you at #ESMOAsia24 ?
Coming to #ESMOAsia24? Please join us for this 'special session' on #cancer #survivorship - Sun Dec 8, 0900-1030 in Hall 407 #survonc #ayacsm
December 1, 2024 at 9:51 AM
Coming to #ESMOAsia24? Please join us for this 'special session' on #cancer #survivorship - Sun Dec 8, 0900-1030 in Hall 407 #survonc #ayacsm